IcoSema, a groundbreaking approach to diabetes management, combines insulin icodec and semaglutide to offer a transformative treatment option. Insulin icodec delivers consistent glucose-lowering effects with once-weekly dosing, while semaglutide, a GLP-1 agonist, stimulates insulin secretion and aids in weight loss. This comprehensive article evaluates the potential of IcoSema from a clinical pharmacology perspective, examining the pharmacokinetics, efficacy, safety, compliance and cost-effectiveness of its individual components, as well as considering comparable combination therapies like iGlarLixi and IDegLira. By analysing these crucial factors, the article aims to determine the potential of IcoSema in the field of diabetes management. The combination of insulin icodec and semaglutide has the potential to provide improved glycaemic control, weight management, and simplified treatment regimens, addressing common challenges faced in diabetes management. Safety, compliance and cost considerations are important aspects of evaluating this combination therapy. Ongoing trials investigating IcoSema are expected to provide valuable insights into its efficacy, safety and comparative effectiveness. By addressing concerns such as potential side effects, individual patient response and drug interactions, healthcare providers can optimize treatment outcomes and enhance the management of type 2 diabetes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1515/jbcpp-2024-0058 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Senile dementia (SD) is a deteriorative organic brain disorder and it comprises Alzheimer's disease (AD) as a major variant. SD is shown impairment of mental capacities whereas AD is degeneration of neurons. According to World Health Organization (WHO) report; more than 55 million peoples have dementia and it is raising 10 million new cases every year.
View Article and Find Full Text PDFDementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
Center for Alzheimer's Research and Treatment, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, USA.
Background: Medical history and healthcare utilization in preclinical Alzheimer's disease (AD) are not well characterized and may reveal indicators associated with asymptomatic stages of AD.
Methods: This retrospective observational study compared 246 Anti-Amyloid Treatment in Asymptomatic AD study (A4) individuals who met elevated brain amyloid eligibility criteria to 121 individuals in the companion Longitudinal Evaluation of Amyloid Risk and Neurodegeneration study (LEARN) who were eligible for A4 except did not meet elevated amyloid eligibility criteria. Matched-controls for A4/LEARN, using a 3:1 match of demographics, Medicare enrollment month, and frailty status, were randomly selected from Medicare beneficiaries without cognitive impairment/dementia claims.
Dementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
New York University, New York, NY, USA.
Background: Adults with comorbidity of cognitive impairment and diabetes is common (19.9%-45.0%) and increasing; however, the evidence is lacking on non-pharmacological behavioral interventions to support cognitive health and diabetes management for individuals with both conditions.
View Article and Find Full Text PDFBackground: It is more ideal to manage dementia patients in memory clinics but not all of them are referred to such clinics. Also, the characteristics of these patients are less studied and local published data is limited. In 2004, the Neuro-cognitive Clinic of Alice Ho Miu Ling Nethersole Hospital was established.
View Article and Find Full Text PDFImplications of Biomaterials for Chronic Wounds.
Mini Rev Med Chem
January 2025
University of Bucharest, Faculty of Biology, DAFAB Department, Splaiul Independentei 91-95, Bucharest, R-050095, Romania.
The use of biomaterials in treating and managing chronic wounds represents a significant challenge in global healthcare due to the complex nature of these wounds, which are slow to heal and can lead to complications such as frequent infections and diminished quality of life for patients. Chronic wounds, which can arise from conditions like diabetes, poor circulation, and pressure sores, pose distinct challenges in wound care, necessitating the development of specialized dressings. The pathophysiology of chronic wounds is thoroughly examined in this article, with particular attention paid to the cellular and molecular defects at work and the therapeutic guidelines.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!